Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis have been revised. It is anticipated that the appraisal will begin in early-August 2023 when we will write to you about how you can get involved.